India's Venus Remedies jumps on FDA approval for anti-mircrobial resistance therapy - TradingView
12 hours ago • Google News
Venus Remedies Limited (VENUSREM)
NSEINR 338.68.3%
Price Chart
Key Statistics
Market Cap
INR 4.67B
P/E Ratio
13.40
Revenue (TTM)
INR 6.48B
Volume
267.56K
52W High
INR 427.90
52W Low
INR 270.25
Dividend Yield
0.00%
Beta
1.27
Technicals
50-Day MA
305.921
200-Day MA
329.4553
52 Week High
427.9
52 Week Low
270.25
About VENUSREM
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, .
Employees
1187
Headquarters
Panchkula, India
CEO
Mr. Pawan Chaudhary
Latest News
US FDA grants QIDP designation to Venus Remedies’ Polymyxin B Formulation - BioSpectrum India
8 hours ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg